Figure 1. GLP-1 (7-37)-induced luciferase expression in HEK293/CRE-Luc/GLP1R cells. After stimulation by agonist GLP-1 (7-37), the cells are determined with Fire-Lumi™ Luciferase Assay System (Cat. No. L00877C-100, Genscript) and the relative luminescence units (RLU) were recorded by plate reader (Pherastar, BMG). The RLU were plotted against the log of the cumulative doses of GLP-1 (7-37) (Mean ± SEM, n = 3). The EC₅₀ of GLP-1 (7-37) on cells was 0.29 nM.

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with GLP-1 (7-37) in HEK293/CRE-Luc/GLP1R cells. d2 acceptor fluorophore-labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in HEK293/CRE-Luc/GLP1R cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Varioskan, ThermoFisher). The EC₅₀ of GLP-1 (7-37) on cells was 0.29 nM.

Figure 3. FACS analysis of cell surface expression of human GLP1R on HEK293/CRE-Luc/GLP1R cells. The HEK293/CRE-Luc/GLP1R cells (blue) and the negative control HEK293 cells (red) were probed using GLP-1-Fc fusion protein (GenScript) and FITC-conjugated goat anti-human IgG (H+L) (Cat. No. A01318, Genscript).

HEK293/CRE-Luc/GLP1R Stable Cell Line

Recombinant HEK293 cells stably overexpress human glucagon-like peptide-1 (GLP1R) on the surface and contain high levels of G protein Gαs to couple with the receptor in downstream signaling pathways.

产品编号	M00562
规格	2 vials 大单询价
数量
价格	询价


联系我们

产品简介

Product Description	Recombinant HEK293 cells stably overexpress human glucagon-like peptide-1 (GLP1R) on the surface and contain high levels of G protein Gαs to couple with the receptor in downstream signaling pathways.
Culture Properties	Adherent.
Stability	Stable through more than 16 passages with no significant changes in assay performance or expression profile.
Size	Two vials of frozen cells (>1×10⁶ per vial in 1 mL)
Storage	Store cells in liquid nitrogen immediately upon receipt. Thaw and recover cells within one year from the date received.

培养条件

Culture Medium	DMEM, 10% FBS, 400 μg/ml Geneticin (Cat. No. 10131-035, Life Technologies), 100 μg/ml Hygromycin B (Cat. No. 10687010, Life Technologies)
Complete Growth Medium	DMEM (Cat. No. 10566, Life Technologies), 10% FBS.
Freeze Medium-DATA	95% FBS (Cat. No. 10099-141, Life Technologies), 5% DMSO (Cat. No. D2650, Sigma)

图例

Figure 1. GLP-1 (7-37)-induced luciferase expression in HEK293/CRE-Luc/GLP1R cells. After stimulation by agonist GLP-1 (7-37), the cells are determined with Fire-Lumi™ Luciferase Assay System (Cat. No. L00877C-100, Genscript) and the relative luminescence units (RLU) were recorded by plate reader (Pherastar, BMG). The RLU were plotted against the log of the cumulative doses of GLP-1 (7-37) (Mean ± SEM, n = 3). The EC₅₀ of GLP-1 (7-37) on cells was 0.29 nM.

Figure 2. Dose dependent stimulation of intracellular cAMP accumulation upon treatment with GLP-1 (7-37) in HEK293/CRE-Luc/GLP1R cells. d2 acceptor fluorophore-labeled cAMP (Cat. No. 62AM4PEC; Revvity) and intracellular cAMP in HEK293/CRE-Luc/GLP1R cells competitively bind with Europium Cryptate-labeled anti-cAMP monoclonal antibody. The FRET signal decreases as the intracellular cAMP concentration rises and was measured by plate reader (Varioskan, ThermoFisher). The EC₅₀ of GLP-1 (7-37) on cells was 0.29 nM.

Figure 3. FACS analysis of cell surface expression of human GLP1R on HEK293/CRE-Luc/GLP1R cells. The HEK293/CRE-Luc/GLP1R cells (blue) and the negative control HEK293 cells (red) were probed using GLP-1-Fc fusion protein (GenScript) and FITC-conjugated goat anti-human IgG (H+L) (Cat. No. A01318, Genscript).

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

HEK293/CRE-Luc/GLP1R Stable Cell Line

资源中心

技术支持

关于我们